ID29107A - Metoda pengobatan iskemia serebral dan penggunaannya eritropoetin atau turunan eritropoetin untuk penggunaan iskemia serebral - Google Patents

Metoda pengobatan iskemia serebral dan penggunaannya eritropoetin atau turunan eritropoetin untuk penggunaan iskemia serebral

Info

Publication number
ID29107A
ID29107A IDW00200101535A ID20011535A ID29107A ID 29107 A ID29107 A ID 29107A ID W00200101535 A IDW00200101535 A ID W00200101535A ID 20011535 A ID20011535 A ID 20011535A ID 29107 A ID29107 A ID 29107A
Authority
ID
Indonesia
Prior art keywords
eritropoetin
cerebral ischemia
treatment
cerebral
ischaemia
Prior art date
Application number
IDW00200101535A
Other languages
English (en)
Inventor
H Ehrenreich
C Gleither
Original Assignee
Ehrenreich Hennelore Cs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7891015&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ID29107(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ehrenreich Hennelore Cs filed Critical Ehrenreich Hennelore Cs
Publication of ID29107A publication Critical patent/ID29107A/id

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
IDW00200101535A 1998-12-14 1999-12-13 Metoda pengobatan iskemia serebral dan penggunaannya eritropoetin atau turunan eritropoetin untuk penggunaan iskemia serebral ID29107A (id)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19857609A DE19857609A1 (de) 1998-12-14 1998-12-14 Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen

Publications (1)

Publication Number Publication Date
ID29107A true ID29107A (id) 2001-07-26

Family

ID=7891015

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW00200101535A ID29107A (id) 1998-12-14 1999-12-13 Metoda pengobatan iskemia serebral dan penggunaannya eritropoetin atau turunan eritropoetin untuk penggunaan iskemia serebral

Country Status (26)

Country Link
US (1) US7514072B1 (id)
EP (1) EP1140139B2 (id)
JP (2) JP4750947B2 (id)
KR (1) KR100774827B1 (id)
CN (1) CN1187085C (id)
AT (1) ATE253932T1 (id)
AU (1) AU766216C (id)
BG (1) BG65417B1 (id)
BR (1) BR9916197A (id)
CA (1) CA2353553C (id)
DE (2) DE19857609A1 (id)
DK (1) DK1140139T4 (id)
ES (1) ES2211218T5 (id)
HK (1) HK1042655B (id)
HU (1) HUP0104709A3 (id)
ID (1) ID29107A (id)
IL (2) IL143579A0 (id)
MX (1) MXPA01005971A (id)
NO (1) NO330079B1 (id)
NZ (1) NZ541591A (id)
PL (1) PL202483B1 (id)
PT (1) PT1140139E (id)
RO (1) RO121409B1 (id)
RU (1) RU2242991C2 (id)
WO (1) WO2000035475A2 (id)
ZA (1) ZA200104626B (id)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19857609A1 (de) 1998-12-14 2000-06-15 Hannelore Ehrenreich Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen
US7309687B1 (en) 1999-04-13 2007-12-18 The Kenneth S. Warren Institute, Inc. Methods for treatment and prevention of neuromuscular and muscular conditions by peripherally administered erythropoietin
KR101012932B1 (ko) * 1999-04-13 2011-02-08 더 케네쓰 에스. 워렌 인스티튜트 인코포레이티드 말초 투여된 에리트로포에틴에 의한 흥분조직의 기능조절법
US7345019B1 (en) 1999-04-13 2008-03-18 The Kenneth S. Warren Institute, Inc. Modulation of excitable tissue function by peripherally administered erythropoietin
US7078376B1 (en) 2000-08-11 2006-07-18 Baxter Healthcare S.A. Therapeutic methods for treating subjects with a recombinant erythropoietin having high activity and reduced side effects
DE10043457A1 (de) * 2000-09-04 2002-03-28 Hannelore Ehrenreich Verfahren zur Behandlung von Schizophrenie und verwandten Psychosen sowie Verwendung von Erythropoietin oder Erythropoietinderivaten zur Behandlung von Schizophrenien und verwandten Psychosen
US7767643B2 (en) 2000-12-29 2010-08-03 The Kenneth S. Warren Institute, Inc. Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
PA8536201A1 (es) * 2000-12-29 2002-08-29 Kenneth S Warren Inst Inc Protección y mejoramiento de células, tejidos y órganos que responden a la eritropoyetina
US6531121B2 (en) 2000-12-29 2003-03-11 The Kenneth S. Warren Institute, Inc. Protection and enhancement of erythropoietin-responsive cells, tissues and organs
US20030072737A1 (en) 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
AR036400A1 (es) 2001-08-30 2004-09-08 Stem Cell Therapeutics Inc Regulacion combinada de la produccion de celulas nerviosas.
ATE541921T1 (de) 2001-09-14 2012-02-15 Stem Cell Therapeutics Inc Prolaktin-induzierte zunahme an neuronalen stammzellen und dessen therapeutische anwendung
DE10219545A1 (de) * 2002-04-26 2003-11-06 Lang Florian Regulation der Apoptose
US7439063B2 (en) * 2002-06-11 2008-10-21 Burnham Institute For Medical Research Neuroprotective synergy of erythropoietin and insulin-like growth factors
DE10234192B4 (de) 2002-07-26 2009-11-26 Epoplus Gmbh Co.Kg Verwendung von Erythropoetin
EP1633383A4 (en) * 2003-03-27 2008-05-21 Janssen Pharmaceutica Nv USE OF ERYTHROPOIETIN FOR RE-ESTABLISHMENT FOLLOWING A CEREBRAL ISCHEMIC ACCIDENT
US7718363B2 (en) 2003-04-25 2010-05-18 The Kenneth S. Warren Institute, Inc. Tissue protective cytokine receptor complex and assays for identifying tissue protective compounds
US20070111932A1 (en) * 2003-07-31 2007-05-17 Stem Cell Therapeutics Inc. Method of enhancing and/or inducing neuronal migration using erythropoietin
WO2005032467A2 (en) 2003-09-29 2005-04-14 Warren Pharmaceuticals, Inc. Tissue protective cytokines for the treatment and prevention of sepsis and the formation of adhesions
UA82561C2 (uk) * 2003-10-23 2008-04-25 Оцука Фармасьютикалз Ко., Лтд. Стерильна ін'єкційна композиція арипіпразолу з контрольованим вивільненням, спосіб її виготовлення та спосіб лікування шизофренії
CA2556266A1 (en) 2004-02-13 2005-08-25 Stem Cell Therapeutics Corp. Use of luteinizing hormone (lh), and chorionic gonadotropin (hcg) for proliferation of neural stem cells and neurogenesis
US9988427B2 (en) 2005-05-13 2018-06-05 Charite Universitaetsmedizen-Berlin Erythropoietin variants
EP1736481A1 (en) 2005-05-13 2006-12-27 Charite Universitätsmedizin-Berlin Erythropoietin variants
CA2622758A1 (en) * 2005-09-15 2007-03-29 Elan Pharma International, Limited Nanoparticulate aripiprazole formulations
WO2007036033A1 (en) * 2005-09-27 2007-04-05 Stem Cell Therapeutics Corp. Oligodendrocyte precursor cell proliferation regulated by prolactin
WO2007106987A1 (en) * 2006-03-17 2007-09-27 Stem Cell Therapeutics Corp. Continuous dosing regimens for neural stem cell proliferating agents and neural stem cell differentiating agents
BRPI0712063A2 (pt) * 2006-06-07 2011-12-20 Chugai Pharmaceutical Co Ltd tratamento de doenças isquêmicas usando eritropoietina
SI2170279T1 (en) * 2007-07-31 2018-04-30 Otsuka Pharmaceutical Co., Ltd. Methods for producing aripiprazole suspension and freeze-dried formulation
RU2446834C2 (ru) * 2010-06-15 2012-04-10 Елена Александровна Лебедева Способ лечения пострадавших с сочетанной черепно-мозговой травмой
WO2012148200A2 (ko) 2011-04-26 2012-11-01 아주대학교 산학협력단 허혈성 혈관 질환 치료시술 보조용 조성물
RU2495688C1 (ru) * 2012-03-28 2013-10-20 Государственное бюджетное учреждение здравоохранения Центр организации специализированной медицинской помощи "Челябинский государственный институт лазерной хирургии" Способ лечения ишемии головного мозга в эксперименте
US9610444B2 (en) 2013-03-15 2017-04-04 Pacesetter, Inc. Erythropoeitin production by electrical stimulation
KR20190052855A (ko) 2017-11-09 2019-05-17 대한제당 주식회사 페길레이션된 에리스로포이에틴을 포함하는 허혈성 뇌질환 치료용 조성물

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ210501A (en) 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
JPS6197229A (ja) 1984-10-18 1986-05-15 Chugai Pharmaceut Co Ltd 安定なエリトロポエチン製剤
IL77081A (en) 1984-12-04 1999-10-28 Genetics Inst Dna sequence encoding human erythropoietin process for the preparation thereof and a pharmaceutical composition of human erythropoietin
US5013718A (en) * 1986-11-21 1991-05-07 Amgen, Inc. Method for treating iron overload using EPO
FR2646438B1 (fr) 1989-03-20 2007-11-02 Pasteur Institut Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration
EP0945515A3 (en) 1989-11-06 2002-08-21 Cell Genesys, Inc. Production of proteins using homologous recombination
ES2151463T5 (es) 1989-12-22 2012-10-29 Merck Serono Sa Constructos de ADN para la activación y la modificación de la expresión de genes endógenos
US5750376A (en) 1991-07-08 1998-05-12 Neurospheres Holdings Ltd. In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny
US5641670A (en) 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
PT101031B (pt) 1991-11-05 2002-07-31 Transkaryotic Therapies Inc Processo para o fornecimento de proteinas por terapia genetica
JP3537151B2 (ja) 1991-12-26 2004-06-14 中外製薬株式会社 脳機能障害による疾患の予防・治療薬
RU2068268C1 (ru) * 1992-03-19 1996-10-27 Учебно-научный центр Медицинского центра при Правительстве РФ Способ профилактики церебро-васкулярных заболеваний
US5614184A (en) 1992-07-28 1997-03-25 New England Deaconess Hospital Recombinant human erythropoietin mutants and therapeutic methods employing them
US5661125A (en) 1992-08-06 1997-08-26 Amgen, Inc. Stable and preserved erythropoietin compositions
TW402639B (en) 1992-12-03 2000-08-21 Transkaryotic Therapies Inc Protein production and protein delivery
BR9406490A (pt) 1993-04-29 1996-03-05 Abbott Lab Análogo de eritropoietina humana,DNA de filamento duplo,vetor de expressão célula de mamiferos em cultura composição farmaceutica segundo e terceiro análogo de eritropoietina humana e processos para fabricar um segundo análogo de eritropoietina e para usar um segundo análogo
CN1057534C (zh) 1993-08-17 2000-10-18 柯瑞英-艾格公司 促红细胞生成素类似物
SE520730C2 (sv) 1995-01-20 2003-08-19 Eskil Elmer Behandling av hjärnischemi och hjärnskador med ett neuroprotektivt läkemedel
US6121246A (en) 1995-10-20 2000-09-19 St. Elizabeth's Medical Center Of Boston, Inc. Method for treating ischemic tissue
US6165783A (en) 1997-10-24 2000-12-26 Neuro Spheres Holdings Ltd. Erythropoietin-mediated neurogenesis
DE19857609A1 (de) 1998-12-14 2000-06-15 Hannelore Ehrenreich Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen
KR101012932B1 (ko) 1999-04-13 2011-02-08 더 케네쓰 에스. 워렌 인스티튜트 인코포레이티드 말초 투여된 에리트로포에틴에 의한 흥분조직의 기능조절법
US20030072737A1 (en) 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs

Also Published As

Publication number Publication date
BG105575A (en) 2002-01-31
AU2283100A (en) 2000-07-03
HK1042655A1 (en) 2002-08-23
DK1140139T4 (da) 2009-06-08
WO2000035475A2 (de) 2000-06-22
KR20010082346A (ko) 2001-08-29
ES2211218T3 (es) 2004-07-01
NO20012896D0 (no) 2001-06-12
DE59907752D1 (de) 2003-12-18
PL349335A1 (en) 2002-07-15
PL202483B1 (pl) 2009-06-30
ES2211218T5 (es) 2009-06-03
WO2000035475A3 (de) 2000-10-19
JP4750947B2 (ja) 2011-08-17
EP1140139A2 (de) 2001-10-10
IL143579A0 (en) 2002-04-21
AU766216C (en) 2004-11-11
BR9916197A (pt) 2001-09-04
HUP0104709A2 (hu) 2002-04-29
NO330079B1 (no) 2011-02-14
HUP0104709A3 (en) 2002-05-28
KR100774827B1 (ko) 2007-11-07
CA2353553C (en) 2011-05-17
NZ541591A (en) 2007-08-31
EP1140139B1 (de) 2003-11-12
CN1187085C (zh) 2005-02-02
NO20012896L (no) 2001-08-14
HK1042655B (zh) 2005-09-23
JP2011079860A (ja) 2011-04-21
DE19857609A1 (de) 2000-06-15
MXPA01005971A (es) 2002-03-27
PT1140139E (pt) 2004-04-30
RU2242991C2 (ru) 2004-12-27
ZA200104626B (en) 2002-09-06
CN1335776A (zh) 2002-02-13
ATE253932T1 (de) 2003-11-15
US7514072B1 (en) 2009-04-07
RO121409B1 (ro) 2007-05-30
CA2353553A1 (en) 2000-06-22
AU766216B2 (en) 2003-10-09
JP2002532432A (ja) 2002-10-02
EP1140139B9 (de) 2004-03-31
BG65417B1 (bg) 2008-07-31
EP1140139B2 (de) 2009-03-18
IL143579A (en) 2007-10-31
DK1140139T3 (da) 2004-03-15

Similar Documents

Publication Publication Date Title
ID29107A (id) Metoda pengobatan iskemia serebral dan penggunaannya eritropoetin atau turunan eritropoetin untuk penggunaan iskemia serebral
WO2004096216A3 (en) Use of a topical medicament comprising riluzole
NO961326L (no) Inhibitorer av -amyloidproteinproduksjon
BR0013540A (pt) Formulações farmacêuticas e seu uso na prevenção de acidente vascular cerebral, diabetes e/ou falha de coração congestiva
ATE245452T1 (de) Hyaluronatlyase als penetrationsförderer in topischen mitteln
ATE200422T1 (de) Verwendung von boswelliasäure und ihren derivaten zur hemmung der normalen und gesteigerten leukozytenelastase- oder plasminaktivität
WO2022192594A3 (en) Nucleic acid molecules and vaccines comprising same for the prevention and treatment of coronavirus infections and disease
BR0201862A (pt) Composições e métodos para tratar ou prevenir convulsões ou ataques apoplécticos
WO2004100893A3 (en) Methods for treatment of inflammatory diseases using ct-3 or analogs thereof
NO20044530L (no) Fremgangsmate for behandling av kognitive forstyrrelser
EA200400436A1 (ru) Медикаменты для профилактики и лечения бромидроза
BR0213479A (pt) Utilização do irbesartan para a preparação de medicamentos úteis para a prevenção ou o tratamento da hipertensão pulmonar
EP1297849A4 (en) CURATIVE AGENT FOR OPTICAL AND SIMILAR NERVE DISEASES
HUP0400737A2 (hu) L-karnitin alkalmazása proteinek stabilizálására szolgáló készítmények előállítására
DE60306503D1 (de) Statin-therapie zur verbesserung der aufrechterhaltung der kognitiven funktion
WO2002076393A3 (en) Antiagionecic, antitumor, chemopreventative agents
DE60004093D1 (de) Pharmazeutische zusammensetzung welche riluzol und gabapentin enthält zur behandung von motoneuronalen krankheiten
DK0659079T3 (da) Transdermalt terapeutisk system med pentylentetrazol som aktivt stof.
IS7418A (is) Sítalópram til að meðhöndla hækkaðan blóðþrýsting
ATE406888T1 (de) Cyanoacrylat-zusammensetzungen für die therapeutische behandlungvon wunden, die eine revision erfordern
WO2010011117A3 (ko) Ｎｄｇａ를 포함하는 트란스글루타미나제 억제용 조성물
SE9901578D0 (sv) New use of substance in PNS
BR0312283A (pt) Combinação compreendendo um agente de alquilação e um agente redutor da atividade de vegf
TW200519078A (en) 2-alkylidene-19-nor-vitamin d derivatives for the treatment of a second hip fracture